Calculus exits Avvio for 5.5x return
Calculus completes exit from Avvio for 5.5x return, a continuation of excellent exits achieved for Calculus investors in the last two years.
Calculus completes exit from Avvio for 5.5x return, a continuation of excellent exits achieved for Calculus investors in the last two years.
The Government is committed to helping entrepreneurial businesses raise growth capital by continued support of EIS and VCT
Destiny Pharma’s potentially revolutionary product ‘XF-73’ progresses into next stage study.
80% of OEM’s customers won’t have to rely on taxpayer support this winter Saving taxpayers over £250m versus full energy price cap payouts Keeping hundreds of businesses afloat and in control of their costs Open Energy Market (OEM), a leading provider of energy procurement services and net zero technologies, today quantifies the taxpayer savings made … Continued
Calculus sponsored the HNW wealth manager of the year award.
Arecor continue to make significant strides proving the strength of their technology.
Scancell continue progress for Modi-2 by in-licencing Vaccitech technology.
Arecor’s subsidiary launch a new treatment option for severe hypoglycaemia for children and adults living with diabetes.
Elizabeth Klein joins Calculus as a Director within the investment team, bringing a wealth of experience.
Scancell said it has enrolled its first patient in the expansion phase of its ModiFY trial.